TRIM29 and neoplasm: TRIM29 promoted the degradation of IGF2BP1 by mediating its K48-type ubiquitination at the Lys440 and Lys450 sites, thereby decreasing the PD-L1 level and acting as a tumor suppressor to promote antitumor T-cell immunity.